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Background: Successful pregnancy outcomes in patients with advanced chronic
kidney disease (CKD) are increasingly common in Western countries. However, in
Korea, the available literature addressing this clinical issue is scarce.
Methods: We reviewed 5 successful parturitions [1 patient with Stage 5 CKD and 4
with maintenance hemodialysis (HD)] at Seoul St. Mary's Hospital over 3 years and
investigated changes in dialysis prescription, anemia management, and the inci-
dence of maternal and neonatal complications.
Results: There were no maternal or neonatal deaths in this cohort. The mean age at
the time of conception and delivery was 35.8 ± 3.7 and 36.2 ± 3.5 years, respectively.
Dialysis patients received more frequent and intensiﬁed HD during pregnancy,
20.0 ± 5.7 h/wk of HD over 5 visits with the ultraﬁltration dose maintained between
1 and 2 kg per session. All patients received erythropoietin-stimulating agents and
iron replacement therapy during pregnancy. The mean hematocrit was 33.1 ± 1.9%
before pregnancy and was well maintained during gestation (33.9 ± 3.8% at the ﬁrst
trimester, 29.2 ± 4.2% at the second trimester, and 33.6 ± 8.7% at delivery). The
mean gestation period was 32.7 ± 4.7 weeks, with 60% of patients experiencing
premature delivery. The primary maternal complication was pre-eclampsia; 3
women developed pre-eclampsia and underwent emergency cesarean sections.
Most neonatal complications were related to preterm birth.
Conclusion: Dialysis-related care and general clinical management improved the
clinical outcome of pregnancy for patients with advanced CKD.
Copyright © 2016. The Korean Society of Nephrology. Published by Elsevier. This is
an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).rnal Medicine, Seoul St.
holic University of Korea,
orea.
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Pregnancy is a challenging prospect for patients with
advanced chronic kidney disease (CKD). Indeed, women with
CKD have an extremely low conception rate because of endo-
crine abnormalities and sexual dysfunction [1]. Even when
fertilization is successful, the clinical outcome of pregnancy is
unfavorable, with a greater frequency of spontaneous abortions
and an increased risk of perinatal mortality.y Elsevier. This is an open access article under the CC BY-NC-ND license
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comes for patients with CKD [2,3]. Furthermore, close attention
to the management of anemia, blood pressure and volume
control, as well as dialysis prescriptions seemed to contribute
to these promising results. However, in Korea, the available
literature addressing this clinical issue is scarce [4e6]. Man-
aging this risky pregnancy complicated by CKD is unusual and
can be a challenging experience for both the patient and her
health care provider.
Herein, we report 5 cases of patients with advanced CKD
who delivered in our medical center and had successful preg-
nancy outcomes. We hope that our ﬁndings will generate in-
terest in this clinically complex issue.Methods
We reviewed the records of womenwith advanced CKDwho
had successfully completed parturition at Seoul St. Mary's
Hospital between January 2012 and December 2014. The study
included patients who conceived when their glomerular
ﬁltration rate (GFR) was severely reduced (GFR < 30 mL/min)
and who maintained their pregnancy beyond the ﬁrst
trimester.
We evaluated the incidence of maternal and neonatal
deaths, pregnancy-related complications, changes in dialysis
prescriptions, and anemia management during pregnancy. A
total of 5 women were included in the study.
From the hospital computer records, we obtained clinical
information, includingmaternal age at conception and delivery,
parity, primary renal disease, other underlying medical condi-
tions, dialysis prescriptions, dose of erythropoietin (EPO) and
iron therapy, and maternal and fetal outcomes. We also
collected biochemical and hematologic data, including com-
plete blood count, urea, creatinine, total protein, albumin, iron,
total iron-binding capacity, and ferritin. Data are presented as
the mean ± standard deviation or counts and percentages to
the nearest 10th.
This study was approved by the Institutional Review Board
of Seoul St. Mary's Hospital (KC15RISI0621).Results
Characteristics of patients
Three of the 5 women were treated in local clinics before
their referral to our center. The mean age at the time of
conception and delivery was 35.8 ± 3.7 and 36.2 ± 3.5 years,
respectively. The mean parity was 0.4, with 3 of the 5 patientsTable 1. Characteristics of patients
Patient Age (y)* Primary
renal disease
Obstetric
historyy
Time on
dialysis (mo)z
Urination
1 38/38 RPGN 1-0-0-1 60.5 No
2 40/40 Unknown 0-0-0-0 99.6 No
3 32/33 Unknown 0-0-2-0 96.1 No
4 37/38 Lupus nephritis 1-0-1-1 24.5 Yes
5 31/32 IgA nephropathy 0-0-1-0 e Yes
*At conception/at delivery.
yRefers to term births-premature births-abortions-living children.
zBefore conception.
IgA, immunoglobulin A; RPGN, rapidly progressive glomerulonephritis.having previously experienced spontaneous abortions. The
primary causes of renal failure were rapidly progressive
glomerulonephritis (n ¼ 1), lupus nephritis (n ¼ 1), and
immunoglobulin A nephropathy (n ¼ 1). Two cases were of
unknown etiology (n ¼ 2). Four of the 5 pregnancies occurred
while patients were on a regular hemodialysis (HD) regimen;
the mean duration of HD before conception was 70.2 ± 35.2
months (Table 1). One predialysis patient had Stage 4 CKD at
the time of conception but developed Stage 5 CKD by the time
of delivery. All patients had maintained good general health
before conception, with mean serum albumin levels of
4.1 ± 0.4 g/dL.
Characteristics of pregnancy
On average, pregnancy was detected at 12.2 ± 6.8 weeks
gestational age (GA). After conﬁrmation of pregnancy, 4 of the
5 patients commenced regular examinations at the obstetrics
clinic in our center, with an average of 12.6 days between
each visit. Fetal biometry, amniotic ﬂuid index, and cervical
length were measured at each appointment. Screening tests
for aneuploidy were performed as scheduled, and the Doppler
indices of placental and uterine blood ﬂow were regularly
monitored. A fetal nonstress test was performed at each visit
in the third trimester or when the patient felt contractions.
The ﬁfth patient, who did not receive care at the obstetrics
clinic in our center, underwent prenatal obstetric care at a
local clinic with nephrology follow-up visits at our center
during her pregnancy. She successfully delivered her newborn
under the care of our multidisciplinary team that included
specialists in nephrology, obstetrics, and neonatology. On
average, the women gained 5.2 ± 2.6 kg during pregnancy.
One patient had a normal spontaneous vaginal delivery, but
the others underwent cesarean sections, including 3 emer-
gency cesarean sections due to pre-eclampsia. Additional
pregnancy-related maternal complications included 2 cases of
polyhydramnios and 1 case of premature rupture of mem-
branes before delivery. Moreover, 3 of the patients who
received treatment for pre-eclampsia required additional
treatment after delivery. One patient, who received intrave-
nous magnesium sulfate for pre-eclampsia, developed
hypermagnesemia with central nervous system manifesta-
tions, and 2 patients required additional treatment for pleural
effusion and acute pulmonary edema (Table 2). During preg-
nancy, the sole predialysis patient experienced a gradual
decrease in renal function, and HD was initiated a month after
delivery.
Characteristics of dialysis
Four dialysis patients received HD for an average of
70.2 ± 35.2 months before conception (Table 1). After the
diagnosis of pregnancy, all dialysis patients received more
frequent and intensiﬁed HD, which was on average 5 times/wk
for a total of 20.0 ± 5.7 hours. The ultraﬁltration dose was
essentially maintained in the range of 1e2 kg/session for all
patients, and the mean interdialytic weight gain just before
delivery was 2.1 ± 0.8 kg (Table 3). The mean predialytic blood
urea nitrogen level during gestation was less than 50 mg/dL in
all patients except Patient 1 (Patient 1, 66.2 ± 22.3; Patient 2,
34.9 ± 6.3; Patient 3, 44.3 ± 27.9; Patient 4, 40.7 ± 11.1; and
Patient 5, 48.2 ± 11.0).
Table 2. Characteristics of pregnancies
Patient Pregnancy
detection
Body
weight (kg)*
Mode of
delivery
Complications
Before delivery After delivery
1 20 GA 57.8/59.7 NSD e e
2 12 GA 50.0/53.5 C-sec PE, PROM e
3 6 GA 50.0/57.8 C-sec PE, polyhydramnios, cervix insufﬁciency Pulmonary edema, pleural effusion
4 18 GA 59.5/64.9 C-sec e e
5 5 GA 41.7/49.3 C-sec PE, polyhydramnios, CKD progression Pulmonary edema, pleural
effusion, hypermagnesemia
*At the start of pregnancy/at the end of pregnancy.
CKD, chronic kidney disease; C-sec, cesarean section; GA, gestational age; NSD, normal spontaneous delivery; PE, pre-eclampsia; PROM, premature
rupture of membrane.
Table 3. Characteristics of dialysis
Patient RRT modality Dialyzer HD frequency (/wk)* HD duration (h/wk)* Interdialytic weight
gain (kg)*
1 HD REXBRANE (Asahi Polysulfone); 1.5 m2 3/5 12/20 2
2 HD Polyamix (polyarylethersulfone,
polyvinylpyrrolidone, polyamide); 1.4 m2
3/6 12/24 1.1
3 HD Polyamix (polyarylethersulfone,
polyvinylpyrrolidone, polyamide); 1.4 m2
3/6 12/24 3
4 HD Polyamix (polyarylethersulfone,
polyvinylpyrrolidone, polyamide); 1.3 m2
2/3 8/12 2.2
*At the start of pregnancy/at the end of pregnancy.
HD, hemodialysis; RRT, renal replacement therapy.
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Three types of EPO-stimulating agents (ESAs) were used.
Three patients received 165.8 IU/kg/wk epoetin alfa at the
beginning of their pregnancy and 161.2 IU/kg/wk epoetin alfa at
the end of their pregnancy. One patient received darbepoetin
alfa at a dose of 2.0 mg/kg/mo at the beginning of her pregnancy
and 3.7 mg/kg/mo at the end of the pregnancy. The last patient
was predialytic and commenced treatment with methoxy
polyethylene glycol-epoetin beta at a dose of 120 mg/mo at 18-
week GA. Although the patient gained weight during preg-
nancy, her dose was not changed. All patients received iron
replacement therapy around the second trimester. The mean
dose of iron was 210.0 mg/wk at the start of the second
trimester and 184.0 mg/wk at the month of delivery (Table 4).
The respective mean levels of hemoglobin and hematocrit
were 11.0 ± 1.0 g/dL and 33.1 ± 1.9% before pregnancy,
10.9 ± 0.9 g/dL and 33.9 ± 3.8% at the ﬁrst trimester, 9.2 ± 1.2 g/
dL and 29.2 ± 4.2% at the second trimester, and 11.3 ± 1.7 g/dL
and 34.0 ± 4.9% at the third trimester, respectively. The meanTable 4. Anemia management
Patient ESA therapy* Iron supplementationy
1 Epoetin alfa 17.3/201.0z 140.0/140.0/140.0
2 Epoetin alfa 240.0/74.8z 0/50.0/50.0
3 Epoetin alfa 240.0/207.8z 0/270.0/270.0
4 Darbepoetin alfa 2.0/3.7x 0/320.0/190.0
5 Methoxy polyethylene
glycol-epoetin b
2.9/2.4x 0/270.0/270.0
*At the start of pregnancy/at the end of pregnancy.
yBefore the pregnancy/at the start of midtrimester/at the end of preg-
nancy (mg/wk).
zIU/kg/wk.
xmg/kg/mo.
ESA, erythropoietin-stimulating agent.transferrin saturation level was 38.6 ± 13.5% before pregnancy,
28.6 ± 1.1% at the ﬁrst trimester, 39.5 ± 13.9% at the second
trimester, and 36.2 ± 19.6% at the third trimester (Fig. 1). None
of the patients required a transfusion during the course of
pregnancy.Blood pressure management
Four patients were treated with a single low-dose medica-
tion for chronic hypertension before pregnancy. Among 2 pa-
tients who had been initially prescribed monotherapy with
5 mg of amlodipine, one later switched to an alternative cal-
cium channel blocker, nifedipine (30 mg), in the second
trimester, and the other received combination therapy with
add-on of atenolol (25 mg/d) in the second trimester. One0
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Figure 1. Average of serum hematocrit level and transferrin saturation
at each pregnancy period.
Hct, hematocrit; TSAT, transferrin saturation.
Table 5. Blood pressure management
Patient Before the pregnancy During the pregnancy At the delivery
1 Amlodipine 5 mg Switch to nifedipine 30 mg at 23 GA Same as before
2 Amlodipine 5 mg Add atenolol 25 mg at 22 GA Hydralazine 10 mg IV for 2 d due to PE
3 e e Hydralazine 5 mg IV for 1 d due to PE
4 Carvedilol 12.5 mg Same as before Same as before
5 Telmisartan 40 mg Discontinuance of telmisartan at pregnancy detection
Start nifedipine 30 mg at 18 GA
Nicardipine 4 mg IV for 2 d due to PE
GA, gestational age; IV, intravenous; PE, pre-eclampsia.
Table 6. Characteristics of neonates
Patient GA at birth Birth weight (g) Apgar scores* Complications NICU admission (d)
1 37 þ 5 2,460 8/9 LBW 0
2 29 þ 3 1,252 1/4 Prematurity, VLBW, RDS, BPD, PDA, IVH, PH 240
3 27 þ 3 1,090 4/8 Prematurity, VLBW, RDS, BPD, IVH, NEC 73
4 37 þ 3 2,330 8/9 LBW 12
5 31 þ 2 1,457 6/8 Prematurity, VLBW, RDS, BPD, IVH, neonatal sepsis 80
*At 1 min/at 5 min after the birth.
BPD, bronchopulmonary dysplasia; GA, gestational age; IVH, intraventricular hemorrhage; LBW, low birth weight; NEC, necrotizing enterocolitis;
NICU, neonatal intensive care unit; PDA, patent ductus arteriosus; PH, pulmonary hypertension; RDS, respiratory distress syndrome; VLBW, very low
birth weight.
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(12.5 mg/d) throughout her pregnancy. One woman who was
taking the angiotensin II receptor antagonist telmisartan,
immediately terminated use of the medication when she
discovered she was pregnant because of its known teratoge-
nicity; she was prescribed 30 mg/d of nifedipine from 18-
week gestation (Table 5). All patients maintained their blood
pressure below 130/80 mmHg throughout pregnancy, except
the situation of pre-eclampsia.
Characteristics and outcomes of neonates
The mean GA was 32.7 ± 4.7 weeks. Premature delivery
occurred in 60% (3 of 5) of patients. Two full-term neonates had
low birth weight (less than 2,500 g), and 3 preterm neonates
had very low birth weight (less than 1,500 g). The mean birth
weight of the newborns was 1,717.8 ± 633.4 g (Table 6).
Immediately after birth, newborns were transferred from the
delivery room to receive individualized postnatal care by neo-
natologists. One healthy term newborn was transferred to the
regular nursery, and the other 4 were admitted to the neonatal
intensive care unit (NICU). The full-term newborn who was
transferred to the NICU received short-term ventilator assis-
tance because of transient hypoxemia and was discharged on
hospital Day 12. However, the preterm newborns developed
intraventricular hemorrhage and respiratory distress syndrome
with bronchopulmonary dysplasia despite surfactant admin-
istration. The postnatal course of these preterm neonates was
also complicated by a large patent ductus arteriosus with heart
failure, necrotizing enterocolitis, and neonatal sepsis. The
average length of stay in the NICU for the preterm neonates was
131.0 ± 94.5 days (Table 6). Except for one newborn who was
transferred to another tertiary hospital at 240 days of age, all
newborns were eventually discharged in good health.
Discussion
Although recent case series and systematic reviews have
reported a trend toward improved pregnancy outcomes for
patients with advanced CKD, in Korea, the pregnancy outcomesin these high-risk patients remain under-reported. Here, we
present recent successful pregnancies inwomenwith advanced
CKD in the Seoul St. Mary's Hospital dialysis center.
Despite the small possibility of conception and maintenance
of pregnancy faced by patients with CKD, in our center, 7
women with CKD successfully delivered newborns. Five of
these patients had a GFR less than 15mL/min/1.73 m2 and were
included in our study. Four of these patients were treated with
HD for an average duration of 70.2 ± 35.2 months before con-
ceptionea far lengthier preconception period of dialysis than
reported by other studies [7,8]. It was encouraging that these
pregnancies in patients with advanced CKD resulted in 5 suc-
cessful deliveries over a 3-year period at a single center.
Most likely, several factors contributed to these positive
results. First, all our patients were in a good general health at
the time of conception. For example, the average level of serum
albumin, which was measured serially during prenatal care,
was 4.1 ± 0.4 g/dL before pregnancy and was maintained above
3.0 g/dL by all patients throughout pregnancy. Because albumin
is considered to be representative of a patient's nutritional and
inﬂammatory status, we can assume that these women were
able to achieve optimal dietary intake and an inﬂammation-
free status before and during gestation. This most likely
contributed to the successful occurrence and maintenance of
their pregnancies.
Well-controlled blood pressure could be another contrib-
uting factor to successful conception and maintenance of
pregnancy. Most patients with CKD have chronic hypertension
and tend to require multidrug treatment. Moreover, patients
who require multiple medications for blood pressure control or
those whose hypertension is poorly controlled are at an
increased risk of adverse pregnancy outcomes, including
maternal morbidity and fetal loss [9]. However, among our
patients, one was normotensive and the others maintained
their blood pressure under control with single, low-dose anti-
hypertensive therapy. Before the development of pre-
eclampsia, blood pressure was maintained below 130/
80 mmHg for all patients during pregnancy. This maintenance
of the maternal blood pressuremay have helped to stabilize the
fetoplacental circulation.
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dialysis are also crucial contributors to these positive outcomes.
To avoid excessive ﬂuid loss and sudden changes in osmolarity,
pregnant patients are recommended a high biocompatibility
dialyzerwith a lower surface area and increased time ondialysis
[2,3,7,10e15]. Frequent dialysis during pregnancymay allow for
better and gentler ﬂuid and blood pressuremanagement, liberal
ﬂuid and diet intake, and greater reductions in the level of urea
[10]. In the present study, all 4 dialysis patients were treated
with a high biocompatible dialyzer with a surface area of less
than 1.5 m2. Moreover, they received regular HD that was
increased after pregnancy conﬁrmation (from11.0± 2.0 h/wk to
20.0 ± 5.7 h/wk), and the ultraﬁltration dose was maintained at
less than 2.0 kg/session. Although several review articles have
suggested that increasing the frequency of HD after the second
trimester to more than 5 sessions/wk might lead to better fetal
outcomes,1 patient in our center received only 3 sessions of HD/
wk until delivery. Two years previously, she got sudden damage
to kidney due to pre-eclampsia and increase in lupus activity
during her ﬁrst delivery. Although she was undergoing less
frequent HD, her daily urine output was maintained at
approximately 1,000 mL, which was sufﬁcient to achieve a
healthy status without signiﬁcant volume overload, uremia, or
electrolyte imbalance. During her second pregnancy 2 years
later, we adjusted her HD frequency from semiweekly to 3 times
a week and monitored her volume and biochemical status. This
HD schedule was well tolerated and was maintained during the
entire gestation. Ultimately, she delivered a healthy, term
newborn. These ﬁndings suggest that, in pregnant patientswith
end-stage renal disease, the level to which the frequency of
dialysis is increased should be individualized.
We used a well-accepted approach toward the management
of anemia. During a healthy pregnancy, erythrocyte volume
increases by an average of 450 mL, and vigorous erythropoiesis
leads to a large requirement for iron. In uncomplicated preg-
nancies, iron supplementation of just 6e7 mg/d is sufﬁcient to
satisfy this requirement [9]. However, because they are often
deﬁcient in EPO, pregnant women with advanced CKD require
supplementation with both iron and EPO to maintain accept-
able hematologic parameters. Pregnant women with CKD who
are anemic have a higher risk of preterm labor [2,16]. The use of
high-dose EPO in combination with iron therapy has also been
shown to eliminate the need for blood transfusions in such
patients [2,7,17e19]. In this study, 3 patients received an ESA at
a higher dosage. The only predialytic patient began treatment
with an ESA midtrimester. Although 1 patient received rather
lower dosage of EPO during pregnancy, hematologic parame-
ters were closely monitored in all patients, and the hemoglobin
and hematocrit levels were largely maintained over 10.0 g/dL
and 30%, respectively. No patient required a blood transfusion
at any time during her pregnancy.
Finally, a multidisciplinary team approach that includes
nephrologists, obstetricians, and neonatologists is likely to have
a positive inﬂuence on pregnancy outcomes for women with
CKD. Our active management of dialysis and anemia treatment
was combined with frequent antenatal obstetric follow-up. In
addition, newborns received immediate, intensive postnatal
care. Pertinent patient information was shared among team
members in advance, enabling the proper handling of adverse
events, even in emergency situations. Although the majority of
neonates were born prematurely, all were discharged from the
hospital alive.Nevertheless, similar to previous studies, there were several
adverse outcomes. Renal dysfunction is known to increase the
risk of pre-eclampsia. In one of the largest case series to date
that included 52 pregnancies, Luders et al [20] reported that
pre-eclampsia was diagnosed in 10 (19.2%) patients and nega-
tively affected the rate of successful deliveries. In our study,
apart from 1 patient who had a normal spontaneous vaginal
delivery, all patients had cesarean sections, with 3 women
undergoing emergency operations due to pre-eclampsia.
Although the patients delivered in a timely fashion before the
development of eclampsia, one patient experienced
hypermagnesemia-induced diplopia and vomiting during
magnesium sulfate therapy for pre-eclampsia. In patients with
advanced CKD who have difﬁculty regulating electrolyte bal-
ance, meticulous care is required when administering with
intravenous magnesium for the management of pre-eclampsia.
The failure to achieve optimal pregnancy weight gain during
pregnancy likely contributed to intrauterine growth restriction.
Pregnant women are encouraged to gain at least 11e12 kg
(0.36e0.45 kg/wk) [9], and dialysis patients require a weight
gain of approximately 0.5 kg/wk to avoid maternal hypotension
and volume depletion [10,18]. The patients in our study, how-
ever, gained an average of just 5.2 kg, which is lower than
recommended andmay explainwhy their babies were small for
their GA. Based on the recommendations outlined in textbooks
and review articles, a weight gain of 0.36e0.5 kg/wk may help
to prevent preterm birth and fetal-growth restriction. In preg-
nant patients with advanced CKD, it is difﬁcult to determine
how much of the weight gain is because of excess ﬂuid rather
than pregnancy-associated weight gain. Nevertheless, these
patients should be encouraged to achieve an optimal preg-
nancy weight gainwith careful weekly examinations to look for
signs of ﬂuid overload.
Consistent with other studies, the incidence of suboptimal
fetal outcomes remained high in women with advanced CKD,
notwithstanding advances in obstetrical and neonatal care [21].
In our investigation, all 5 newborns were small for their GA and
3 of them experienced various complications related to preterm
delivery. Four newborns were admitted to the NICU, for an
average of 81 days, and one of them was transferred to the
neonatal care unit at another center on hospital Day 240.
Although there was no neonatal death during hospitalization in
ourmedical center, wedo not have follow-up information about
the newborn who was transferred to another medical center.
Thus, we cannot exclude the possibility of an infant death.
Our study has several limitations. First, this is an observa-
tional study, and the number of patients included is too small to
establish a causal relationship between kidney disease and
adverse maternal and fetal outcomes. Second, we did not have
objective data to evaluate the adequacy of dialysis or a body
water-indexed clearance  time product (Kt/V). Nevertheless,
this study is meaningful because it is the ﬁrst report in Korea
that includes 5 consecutive cases of pregnant patients with
advanced CKD who achieved a successful pregnancy outcome.
We hope that our experience will generate interest in these
high-risk pregnancies and help to guide clinical management of
similar patients.
In summary, our article describes successful pregnancy
outcomes in 5 women with advanced CKD. Clearly, the small
number of patients necessitates a larger scale observational
study. Nevertheless, we cautiously conclude that these
encouraging outcomes resulted from the maintenance of good
Chang et al / Outcomes of pregnant women with CKD 89general health before conception and intensive multidisci-
plinary management after pregnancy conﬁrmation. The rate
of neonatal complications is still high and remains to be
addressed. We hope that our report will be helpful to health
care providers in counseling and managing women with
advanced CKD during pregnancy.Conﬂicts of interest
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